Brief: Eisai & Biogen Say U.S. FDA Accepts Leqembi Supplemental Biologics License Application As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Under Priority Review
25/01/2026 23:36
Jan 25 (Reuters) - Eisai Co Ltd 4523.T: FDA ACCEPTS LEQEMBI® IQLIKTM (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER PRIORITY REVIEW Source text: ID:nPn22MRca Further company coverage: [4523.T BIIB.O] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China